-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Diabetes is a metabolic disease.
The number of diabetic patients in China is huge, and the incidence is increasing day by day, and they are getting younger and younger
.
According to new data released by the International Diabetes Federation (IDF) in 2021, the number of people with diabetes in China has reached 140 million
.
That is, 1 in 10 people may be diabetic
.
Domestic diabetic patients still have a large unmet demand, which also means that the market space for hypoglycemic drugs is broad
.
According to the Frost & Sullivan report, the global market for type 2 diabetes alone has reached US$70 billion
.
Facing the huge market of diabetes drugs, many pharmaceutical companies are competing for layout, and the market competition is becoming more and more fierce
.
With the increased investment in research and development of enterprises, accelerated drug approval and review, and the support of capital, news of the listing of hypoglycemic drugs in the domestic market has continued to spread in recent years
.
For example, just recently, Novo Nordisk held a press conference on the launch of Novoyi (insulin degludec and liraglutide injection) in China
.
The drug was approved by the State Food and Drug Administration in 2021 for the treatment of adult patients with type 2 diabetes mellitus (T2DM) with poor glycemic control
.
On March 2, Sihuan Pharmaceutical announced that its non-wholly-owned subsidiary Huisheng Bio's new oral diabetes drug plus agliflozin's marketing application has been accepted by the State Food and Drug Administration
.
The product is a class 1 hypoglycemic innovative drug independently developed in China and has reached the end point of Phase III clinical trials.
The acceptance of the listing application in China this time marks the company's breakthrough in the field of original research and innovative drugs for the treatment of diabetes
.
At the end of 2021, Hengrui's new class 1 hypoglycemic drug, Proline Henggliflozin Tablets, was approved for marketing.
This product is an innovative drug independently developed by China and has independent intellectual property rights.
It is suitable for improving the blood sugar control of adult patients with type 2 diabetes
.
On October 19, 2021, Chipchip announced that its self-developed and produced original innovative drug "Siglitastat Sodium" was approved by the State Food and Drug Administration, becoming the world's first PPAR full agonist approved for the treatment of type 2 diabetes.
.
In addition, there are still a number of hypoglycemic drugs currently in clinical, review and approval pending listing
.
For example, the marketing application of Hengrui’s other new class 1 hypoglycemic drug, Retagliptin Phosphate Tablets, is under review and approval, and products such as HR17031 injection, INS068 injection, and Noriglycopeptide injection have also been approved for clinical trials
.
According to industry insiders, in general, the common clinical diabetes drugs include several categories: insulin and its analogs, oral hypoglycemic drugs and GLP-1 receptor agonists
.
Among them, in China's hypoglycemic drug market, traditional hypoglycemic drugs such as biguanides, α-glucosidase inhibitors, and insulin are mainly used
.
It is foreseeable that under the background of the continuous innovation of domestic hypoglycemic drugs, it will provide more new choices for clinicians, bring more hope for the majority of diabetic patients, and inject new strength into the development of China's health cause
.
From the perspective of companies that are deploying the diabetes market, the industry believes that the domestic hypoglycemic drug market has entered a situation where a hundred schools of thought contend, and competing products are becoming increasingly fierce.
Driven by policies such as medical insurance and centralized procurement, drug price reductions have become a major trend.
It is expected that the reshuffle of the entire diabetes market will further accelerate in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The number of diabetic patients in China is huge, and the incidence is increasing day by day, and they are getting younger and younger
.
According to new data released by the International Diabetes Federation (IDF) in 2021, the number of people with diabetes in China has reached 140 million
.
That is, 1 in 10 people may be diabetic
.
Domestic diabetic patients still have a large unmet demand, which also means that the market space for hypoglycemic drugs is broad
.
According to the Frost & Sullivan report, the global market for type 2 diabetes alone has reached US$70 billion
.
Facing the huge market of diabetes drugs, many pharmaceutical companies are competing for layout, and the market competition is becoming more and more fierce
.
With the increased investment in research and development of enterprises, accelerated drug approval and review, and the support of capital, news of the listing of hypoglycemic drugs in the domestic market has continued to spread in recent years
.
For example, just recently, Novo Nordisk held a press conference on the launch of Novoyi (insulin degludec and liraglutide injection) in China
.
The drug was approved by the State Food and Drug Administration in 2021 for the treatment of adult patients with type 2 diabetes mellitus (T2DM) with poor glycemic control
.
On March 2, Sihuan Pharmaceutical announced that its non-wholly-owned subsidiary Huisheng Bio's new oral diabetes drug plus agliflozin's marketing application has been accepted by the State Food and Drug Administration
.
The product is a class 1 hypoglycemic innovative drug independently developed in China and has reached the end point of Phase III clinical trials.
The acceptance of the listing application in China this time marks the company's breakthrough in the field of original research and innovative drugs for the treatment of diabetes
.
At the end of 2021, Hengrui's new class 1 hypoglycemic drug, Proline Henggliflozin Tablets, was approved for marketing.
This product is an innovative drug independently developed by China and has independent intellectual property rights.
It is suitable for improving the blood sugar control of adult patients with type 2 diabetes
.
On October 19, 2021, Chipchip announced that its self-developed and produced original innovative drug "Siglitastat Sodium" was approved by the State Food and Drug Administration, becoming the world's first PPAR full agonist approved for the treatment of type 2 diabetes.
.
In addition, there are still a number of hypoglycemic drugs currently in clinical, review and approval pending listing
.
For example, the marketing application of Hengrui’s other new class 1 hypoglycemic drug, Retagliptin Phosphate Tablets, is under review and approval, and products such as HR17031 injection, INS068 injection, and Noriglycopeptide injection have also been approved for clinical trials
.
According to industry insiders, in general, the common clinical diabetes drugs include several categories: insulin and its analogs, oral hypoglycemic drugs and GLP-1 receptor agonists
.
Among them, in China's hypoglycemic drug market, traditional hypoglycemic drugs such as biguanides, α-glucosidase inhibitors, and insulin are mainly used
.
It is foreseeable that under the background of the continuous innovation of domestic hypoglycemic drugs, it will provide more new choices for clinicians, bring more hope for the majority of diabetic patients, and inject new strength into the development of China's health cause
.
From the perspective of companies that are deploying the diabetes market, the industry believes that the domestic hypoglycemic drug market has entered a situation where a hundred schools of thought contend, and competing products are becoming increasingly fierce.
Driven by policies such as medical insurance and centralized procurement, drug price reductions have become a major trend.
It is expected that the reshuffle of the entire diabetes market will further accelerate in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
